Inclusion criteria

Singleton pregnancy

After 28 weeks of gestation

Exclusion criteria

Patients with

Diabetes

Renal failure

Previous h/o Haemolytic anemia

Multiple pregnancy

Smoking and alcoholism

Liver disease

Hepatotoxic drug

Stroke, coronary artery disease

Chronic lung disease connective tissue disorders

Upon meeting the inclusion criteria, a thorough obstetric history and examination were conducted for each enrolled patient. Blood pressure (BP) was measured using an LED mercury sphygmomanometer, with readings taken either in the sitting or supine position. The zero level of the apparatus was aligned with the level of the heart, and BP was assessed in both arms. A cuff that fit snugly around the arm was used: a standard cuff was employed for arm circumferences of 33 cm or less, while a larger cuff (15×35 cm) was used for arm circumferences greater than 33 cm. The lower edge of the cuff was positioned 2.5 cm above the antecubital fossa. First, systolic blood pressure was measured at the brachial artery using the palpatory method. Subsequently, it was measured using the auscultatory method at Korotkoff phase I for systolic pressure and Korotkoff phase V (K5) for diastolic pressure. If K5 was absent, diastolic pressure was recorded at Korotkoff phase IV. Routine laboratory tests included a complete blood count, ABORh, VDRL, Anti-HIV, Anti-HCV, HBsAg, oral glucose tolerance test (OGTT), random blood sugar, and a complete urine analysis. Additional laboratory tests included liver function tests, renal function tests, serum uric acid, serum lactate dehydrogenase, peripheral blood film, prothrombin time index, and either an on-spot urinary protein-to-creatinine ratio or urine albumin measured by the dipstick method. Fundoscopy was recommended for all enrolled patients. Serum LDH test was done in all the patients using L TO P-IFCC method with a reference range of 120-246 U/L.

Statistical Analysis: The data was collected systematically and edited after collection. The data was then entered into computer and statistical analysis of the results was obtained by using windows based computer software devised with Statistical Packages for Social Sciences (SPSS-22) (SPSSS Inc, Chicago, IL, USA). The results were presented in tables and graphs. Continuous variables were expressed as mean with standard deviation and categorical variables as count with percentage. Independent ‘t’ test, One Way ANOVA and Pearson’s correlation was used for data analysis in ICP and NON ICP patients.

1.  Mean (average) x = Total of the all values Number of values∑nn

2. Chi square

X2=∑(o-e)2e

Where 

o = observed value

e = expected value

3. Standard deviation of observation (S.D) =

s=∑(x-x-)2n-1

Where

x = mean x

n= number of observation

4. d.f = (column-1) (row-1)

Distribution of study participants according to the serum LDH levels and correlation with maternal outcomes

Maternal outcome and LDH levels among study participants were cross-tabulated and analyzed, and it was found that the mean LDH level was 1303.600 ± 465.0186 IU in HELLP patients and 656.296 ± 322.7073 IU in non-HELLP patients. In patients experiencing abruption, the mean LDH level was 947.263 +/-403.6658 IU, while in those without abruption, it was 637.355 +/- 320.5428 IU. In patients with maternal mortality, the mean level of LDH was 321; in those without maternal mortality, it was 661.158.The statistical analysis of the data shows a statistically significant correlation (p < 0.05) between the study groups' LDH levels, HELLP syndrome, abruption, and maternal death.

In our study, we observed that among patients with serum LDH levels below 600 IU/L, 15.79% had abruptio placenta while 58.68% did not have abruption. For those with serum LDH levels between 601-800 IU/L, 31.58% had abruptio placenta and 28.10% did not have abruption. In patients with serum LDH levels exceeding 800 IU/L, 52.63% had abruptio placenta and 13.22% did not have abruption. The mean LDH level was 947.263 ± 403.6658 IU in patients with abruption and 637.355 ± 320.5428 IU in patients without abruption. In our study, we found a significant correlation between serum LDH levels and the occurrence of abruptio placenta.

In our study, we observed that no patient with serum LDH levels below 600 IU/L had HELLP syndrome. Among those with serum LDH levels between 601-800 IU/L, 20% had HELLP syndrome, while 28.89% did not. For patients with serum LDH levels exceeding 800 IU/L, 80% had HELLP syndrome, and 16.30% did not. The mean LDH level in patients with HELLP syndrome was 1303.600 ± 456.018 IU, significantly higher than the 656.296 ± 322.703 IU observed in patients without HELLP. Our study found a significant correlation between heightened serum levels of LDH and the occurrence of HELLP syndrome.

In our study, we found that none of the patients with serum LDH levels below 600 IU/L experienced maternal mortality. Similarly, there were no cases of maternal mortality among patients with serum LDH levels between 601-800 IU/L. However, among patients with serum LDH levels exceeding 800 IU/L, 100% experienced maternal mortality, while 17.99% did not. The mean LDH level in patients with maternal mortality was 3217.000 ± 0.000 IU, significantly higher than the 661.158 ± 273.9175 IU observed in patients without maternal mortality. Our study demonstrated a significant correlation between heightened levels of serum LDH and the occurrence of maternal mortality.

Distribution of study participants according to the serum LDH levels and correlation with perinatal outcomes

In our study, we observed that among patients with serum LDH levels below 600 IU/L, 21.62% had intrauterine growth restriction (IUGR), while 64.08% did not. For those with serum LDH levels between 601-800 IU/L, 29.73% had IUGR, and 28.16% did not. Among patients with LDH levels exceeding 800 IU/L, 48.65% had IUGR, and 7.77% did not. Our findings indicate a significant correlation between heightened levels of serum LDH and the occurrence of IUGR.

In our study, we observed that among patients with serum LDH levels below 600 IU/L, 33.33% had IUD, while 53.73% did not. For those with serum LDH levels between 601-800 IU/L, 16.67% had IUD, and 29.10% did not. Among patients with LDH levels exceeding 800 IU/L, 50% had IUD, and 17.16% did not. Our findings indicate a significant correlation between heightened levels of serum LDH and the occurrence of IUD.

Serum LDH levels in preeclamptic-eclamptic pregnant women group

In the present study, LDH levels greater than 800 IU/L were found in 75% of patients in the eclampsia group (6 patients), 37.25% of patients in the severe preeclampsia group (19 patients), and 1.23% of patients in the mild preeclampsia group (1 patient). Additionally, LDH levels between 601 and 800 IU/L were noted in 43.14% of patients with severe preeclampsia (22 patients), 25% of patients with eclampsia (2 patients) and 19.75% of patients with mildly preeclampsia (16 patients). The mean serum LDH levels were 1495.000±859.1230 IU/L in the eclampsia group, 804.569±224.5519 IU/L in the severe preeclamptic group, and 520.062±110.3944 IU/L in the mild preeclampsia group.

In a study conducted by Eleti et al.^[10] in 2023, it was found that serum levels of LDH exceeding 800 IU/L were significantly more in the eclamptic group (60% or 9 patients), in the severely preeclampsia group (40% or n=16 patients), and the mildly preeclamptic group (10% or n=6 patients), with none in the normotensive group (p < 0.0001). Similarly, LDH levels between 600 and 800 IU/L were significantly higher in the severe preeclampsia group (37.5% or 15 patients), the eclampsia group (33.33% or 5 patients), and the mild preeclampsia group (21.66% or 13 patients) compared to the normotensive group (1.73% or 2 patients) (p < 0.0001). The mean serum LDH levels in eclamptic group was 1515.86 ± 754.13 IU/L, 932.20 ± 448.28 IU/L in the severely preeclampsia group, and 580.56 ± 213.21 IU/L in the mildly preeclampsia group.

In a study by Jaiswar et al.^[11] in 2011, it was observed that most patients with mildly preeclampsia had LDH levels below 600 IU/L, with a mean value of 278.3 ± 119.2 IU/L. Only two(n=2) patients (5.7%) had serum levels of LDH between 600 and 800 IU/L, with a mean LDH level of 400.45 ± 145.21 IU/L. Among the 36 cases of severe preeclampsia, 58.3% (21 cases) had serum levels of LDH below 600 IU/L, 13.9% (5 cases) had levels between 600 and 800 IU/L, and 27.7% (10 cases) had levels more than 800 IU/L, with a mean LDH level of 646.95 ± 401.64 IU/L. In the eclampsia group, 69.4% (25 patients) had levels above 800 IU/L, 19.4% (7 patients) had levels of serum LDH between 600 and 800 IU/L, and 11.1% (4 patients) had levels of LDH below 600 IU/L, with a mean LDH level of 1648.10 ± 1992.29 IU/L. The data clearly indicate a significant raise in serum LDH levels with the complication of disease (P<0.001).

Serum LDH and maternal complications

In our study, we observed that Among patients with serum levels of LDH below 600 IU/L, there were 3 (15.79%) cases of abruptio, no cases of HELLP syndrome and no maternal mortality. In the group with serum LDH levels between 601 and 800 IU/L, there were 6 (31.58%) cases of abruptio, 1(20%) case of HELLP syndrome, and no maternal mortality. For patients with LDH levels exceeding 800 IU/L, there were 10(52.63%) cases of abruptio, 4 (80%) cases of HELLP syndrome, and 1(100%) maternal mortality.

The findings of our study align with those of Jaiswar et al. ^[11] who reported that only one case of abruptio placenta occurred in patients with serum levels of LDH between 600-800 IU/L. In contrast, among those with LDH levels exceeding 800 IU/L, there were eight cases of abruptio placenta, HELLP syndrome and pulmonary edema. Similar to our study, their study also demonstrated a statistically significant correlation of raised incidence of maternal complications with higher serum levels of LDH (p < 0.001).

Mary et al.^[12] similarly found a raised incidence of maternal complications with increasing serum levels of LDH. In their study, 94.3% of patients with serum levels of LDH greater than 800 IU/L developed complications, including eclampsia (38.8%), abruptio placenta (22.2%), HELLP syndrome (11.1%).In comparison, 13.6% of patients with LDH levels between 600-800 IU/L experienced complications such as eclampsia (6.8%) and abruptio placenta (3.4%), with these findings also being statistically significant. High serum levels of LDH were strongly correlated with significant impairments in renal and liver function.

Prajapati and Maitra et al.^[13] also documented a raised incidence of maternal adverse outcomes with rising serum levels of LDH. In their study, among patients with LDH levels greater than 800 IU/L, 36.3% developed eclampsia, 12.12% experienced abruptio placenta, 62.5% had HELLP syndrome, 24.24% required maternal ICU admission, and 3.03% resulted in maternal death. The majority (62.5%) of cases with LDH levels greater than 800 IU/L had complications (p < 0.001). In the same study, for LDH levels between 600-800 IU/L, maternal complications included HELLP syndrome (8.33%), abruptio placenta (4.1%), pulmonary edema (4.1%), and maternal ICU admission (4.16%). For LDH levels below 600 IU/L, complications included HELLP syndrome (2.02%), eclampsia (5.05%) and abruptio placenta (2.02%).

Perinatal outcome

In our study, 7.84% of patients with severe preeclampsia experienced intrauterine demise, while 25% of patients with eclampsia had intrauterine demise. P-value is significant.

Panda et al.^[14] conducted the study reported that 60 cases, accounting for 14.9%, resulted in perinatal mortality. This rate was significantly higher among women with eclampsia and severe preeclampsia, with a p-value of less than 0.0001, indicating strong statistical significance. Moreover, perinatal mortality was more prevalent in cases of eclampsia compared to severe preeclampsia, also with a p-value of less than 0.0001.

Serum LDH levels and its correlation with perinatal outcomes

In our study, In patients with LDH levels below 600 IU/L, there were 8 (21.62%) cases of intrauterine growth restriction (IUGR), 2(33.33%) cases of intrauterine death (IUD). For patients with LDH levels between 601-800 IU/L, there were 11(29.73%) cases of IUGR, 1 (16.67%) case of IUD, 13(37.14%) NICU admissions. In patients with serum levels of LDH exceeding 800 IU/L, there were 18 (48.65%)cases of IUGR, 3 (50%)cases of IUD, 20(57.14%) NICU admissions, The p-value is significant for all outcomes.

Eleti et al.^[10] conducted a study in 2023 observed the outcomes in patients with varying LDH levels. They found that among patients with serum levels of LDH below 600 IU/L, , 13 (26%) had intrauterine growth restriction (IUGR), and none had intrauterine death (IUD). In patients with serum levels of LDH between 600 and 800 IU/L, 17 (60.7%) experienced IUGR, and 1 (3.57%) had an IUD. Among those with LDH levels greater than 800 IU/L, 11 (50%) had IUGR, and 3 (13.6%) had an IUD.

According to Gupta et al.,^[9] in 2019, low birth weight occurred in 21(39.6%), with LDH levels below 600 IU/L. In patients with LDH levels between 600-800 IU/L, 18(66%) had low birth weight. In patients with LDH levels above 800 IU/L,17(85%) had low birth weight.

Lavanya et al.^[15] in 2021 reported that 4(7.8%) intrauterine growth restriction (IUGR),1(2%) had intrauterine fetal demise in patients with LDH levels below 600 IU/L.1(3.4%)intrauterine growth restriction (IUGR),none of the patient had intrauterine fetal demise in patients with LDH levels between 600-800 IU/L.3(15%) had IUGR with LDH levels above 800 IU/L.